2096455-90-0
中文名称 | 2096455-90-0 |
---|---|
中文同义词 | 化合物 T12435 |
英文名称 | PF-3893787 hydrochloride |
英文同义词 | PF-3893787 hydrochloride;Adriforant hydrochloride |
CAS号 | 2096455-90-0 |
分子式 | C13H25ClN6O |
分子量 | 316.83 |
EINECS号 | |
相关类别 | |
Mol文件 | 2096455-90-0.mol |
结构式 | ![]() |
2096455-90-0 性质
储存条件 | Store at -20°C |
---|---|
溶解度 | 二甲基亚砜:≥ 83.33 mg/mL(224.16 mM) |
形态 | 固体 |
颜色 | 白色至米白色 |
Ki: 2.4 nM (H4R bind), 1.56 nM (H4R func)
Adriforant is tested and observed binding K i =2.4 nM and functional K i =1.56 nM for H4R. Data from functional assays produce convergent projections of the free plasma efficacious concentration and Adriforant (Compound 13) is fast on/fast off on rhH4R. The in vitro IC 50 on human native isolated eosinophils assessing actin polymerisation is 1.16 nM and assuming need 10 times the IC 50 for >90% receptor occupancy (and therefore near complete inhibition of the response) suggested a concentration of 12 nM. The data in the whole blood GAFS assay demonstrates that the imetit induced shape change is completely blocked at a total blood concentration of 30 nM (which correcting for PPB and blood partitioning equates to approximately 10 nM free). For the purpose of dose projection and safety margin calculation, a Ceff/Cmin concentration of 10-15 nM is used.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 5mg | 800元 |
2024/04/30 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 10mM * 1mLin DMSO | 880元 |